Clinical Trials in Hepatocellular Carcinoma: An Update

被引：54

作者：

Shen, Ying-Chun ^{[1
,2
]}

Lin, Zhong-Zhe ^{[1
,2
,3
]}

Hsu, Chih-Hung ^{[1
,2
,3
,4
]}

Hsu, Chiun ^{[1
,2
,3
,4
]}

Shao, Yu-Yun ^{[2
,4
]}

Cheng, Ann-Lii ^{[2
,3
,4
]}

机构：

[1] Natl Taiwan Univ, Natl Ctr Excellence Clin Trial & Res, Taipei, Taiwan

[2] Natl Taiwan Univ, Dept Oncol, Taipei, Taiwan

[3] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[4] Natl Taiwan Univ, Sch Med, Grad Inst Oncol, Taipei, Taiwan

来源：

LIVER CANCER | 2013年 / 2卷 / 3-4期

关键词：

Clinical trial; Hepatocellular carcinoma; Molecular targeted therapy; TRANSARTERIAL CHEMOEMBOLIZATION PLUS; PHASE-II TRIAL; ARTERIAL CHEMOEMBOLIZATION; BEVACIZUMAB; SORAFENIB; THERAPY; CANCER; COMBINATION; TIVANTINIB; ERLOTINIB;

D O I：

10.1159/000343850

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The success of sorafenib has spurred an explosive increase of clinical trials testing novel molecular targets and other agents in the treatment of hepatocellular carcinoma (HCC). The paradigm of the studies has been characterized by three noticeable changes. First, the molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for advanced HCC treatment. Agents targeting EGFR, FGFR, PI3K/Akt/mTOR, TGF-beta, c-Met, MEK, IGF signaling, and histone deacetylase have been actively explored. Second, the target indication has shifted from advanced stage to early or intermediate stages of disease. The feasibility of combining locoregional therapies and targeted agents, and the use of novel agents after curative treatments are currently under active investigation. Finally, the therapeutic strategy has shifted from monotherapy to combination targeted therapy. We aim to provide a comprehensive overview of newly disclosed and ongoing clinical trials for the treatment of HCC. Copyright (C) 2013 S. Karger AG, Basel

引用

页码：345 / 364

页数：20